Mostrando 10 resultados de: 10
Filtros aplicados
Subtipo de publicación
Article(10)
Publisher
Diabetes Care(2)
The Lancet(2)
The Lancet Diabetes and Endocrinology(2)
Diabetes, Obesity and Metabolism(1)
International Journal of Cardiology(1)
Área temáticas
Enfermedades(9)
Farmacología y terapéutica(5)
Fisiología humana(5)
Medicina y salud(3)
Problemas sociales y servicios a grupos(3)
Área de conocimiento
Diabetes(5)
Medicina interna(5)
Cognición(2)
Enfermedad cardiovascular(2)
Epidemiología(1)
Origen
scopus(10)
Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial
ArticleAbstract:Palabras claves:CVD risk, Dysglycemia, handgrip, Muscle strength, Type 2 DiabetesAutores:Bosch J.J., Cohen D.D., Dyal L., Gerstein H.C., Gomez-Arbelaez D., PATRICIO LOPEZ -JARAMILLO, Yusuf S.Fuentes:googlescopusAvailability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study
ArticleAbstract: Background: Data are scarce on the availability and affordability of essential medicines for diabetePalabras claves:Autores:Alhabib K.F., Avezum A.J., Cheng X., Chifamba J., Chow C.K., Corsi D.J., Dagenais G.R., Dans A.M., Egbujie B.A., Gerstein H.C., Gupta R., Hu W., Iqbal R., Islam S., Keskinler M.V., Khatib R., Kruger L., Kumar R., Lanas F.T., Lear S.A., Mckee M., Mohammadifard N., Mohan V., Mony P.K., Noorhassim I., Orlandini A., PATRICIO LOPEZ -JARAMILLO, Ramasundarahettige C., Rangarajan S., Rosengren A., Teo K.K., Vijayakumar K., Wei L., Yeates K.E., Yusoff K., Yusuf R., Yusuf S., Yusufali A.M., Zatońska K., Zhou Y.Fuentes:googlescopusEffect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigatePalabras claves:Autores:Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:googlescopusEffect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: The glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)
ArticleAbstract: OBJECTIVE-To evaluate the effects of insulin glargine and n-3 polyunsaturated fatty acid (n- 3FA) suPalabras claves:Autores:Bosch J.J., DIaz R., Dyal L., Gerstein H.C., Hâncu N., Hanefeld M., Krum H., Lonn E.M., McQueen M.J., PATRICIO LOPEZ -JARAMILLO, Ramachandran A., Rydén L.E., Smith S., Yusuf S.Fuentes:googlescopusDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
ArticleAbstract: Background: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascularPalabras claves:Autores:Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Riesmeyer J.S., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.Fuentes:googlescopusDulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
ArticleAbstract: Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people wPalabras claves:Autores:Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Botros F.T., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.Fuentes:googlescopusNovel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
ArticleAbstract: Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationshiPalabras claves:cardiovascular events, cognitive impairment, Composite outcome, death, Geometric mean, MACE, risk factor, strokeAutores:Angelyn Bethel M., Basile J.N., Cardona-Munoz E.G., Conget I., Cukierman-Yaffee T., Dagenais G.R., Franek E., Gerstein H.C., Hall S., Hâncu N., Jansky P., Lakshmanan M., Lanas F., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Ramasundarahettige C., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusVariations in diabetes prevalence in low-, middle-, and high-income countries: Results from the prospective urban and rural epidemiological study
ArticleAbstract: OBJECTIVE: The goal of this study was to assess whether diabetes prevalence varies by countries at dPalabras claves:Autores:Avezum A.J., Chifamba J., Dagenais G.R., DIaz R., Gejie Y., Gerstein H.C., Gupta R., Iqbal R., Jiankang L., Kelishadi R., Kruger A., Kumar R., Kutty V.R., Lanas F., Lear S.A., McQueen M.J., Mohan V., Mony P.K., Noorhassim I., Oguz A., PATRICIO LOPEZ -JARAMILLO, Peer N., Rahman O., Rangarajan S., Rosengren A., Teo K.K., Wenqing D., Xiulin B., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K., Zhang X.Fuentes:googlescopusThe association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial
ArticleAbstract: We compared cardiovascular and other outcomes in patients with dysglycaemia with or without anti-gluPalabras claves:anti-GAD, CVD, Type 2 DiabetesAutores:Birkeland K.I., Gerstein H.C., Grill V., Lee S.F., McQueen M.J., PATRICIO LOPEZ -JARAMILLO, Wium C.Fuentes:googlescopusThe effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptPalabras claves:Autores:Atisso C.M., Avezum A.J., Basile J.N., Botros F.T., Colhoun H.M., Conget I., Cushman W.C., DIaz R., Dyal L., Gerstein H.C., Hall S., Hâncu N., Hanefeld M., Hart R.G., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopus